SCHEMBL6286661

SCHEMBL6286661

CCCc1nc2cc(OCC3CO3)ccc2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
TP53 P04637 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
TSHR P16473 3/20 0.44
HIF1A Q16665 2/20 0.44
CYP3A4 P08684 1/20 0.44
FGFR1 P11362 1/20 0.42
SRC P12931 1/20 0.42
KMT2A Q03164 7/20 0.41
MAPT P10636 5/20 0.41
MEN1 O00255 5/20 0.41
HPGD P15428 4/20 0.41
CYP1A2 P05177 1/20 0.41
PPARG P37231 1/20 0.41
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 4/20 0.38
LMNA P02545 3/20 0.38
PKM P14618 2/20 0.38
GAA P10253 2/20 0.38
NPC1 O15118 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5901373 0.82 PDE10A (0.51) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL3960133 0.82 PDE10A (0.51) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL3960135 0.82 PDE10A (0.51) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL5901698 0.76 FGFR1 (0.50) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL5965259 0.76 FGFR1 (0.50) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL5228972 0.76 FGFR1 (0.50) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL8054624 0.75 ALDH1A1 (0.51) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL5227730 0.72 TDP1 (0.51) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL6287497 0.71 HTT (0.43) ALDH1A1TP53SMN1; SMN2TSHRHIF1A
SCHEMBL24059195 0.71 ALDH1A1 (0.54) ALDH1A1TP53SMN1; SMN2TSHRHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6849632-B2 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. (US) 2005-02-01 US disclosed
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ZABLOCKI JEFF (US) 2004-09-30 US disclosed
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives CV THERAPEUTICS, INC. 2003-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192702-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885TP53 3711/4885SMN1; SMN2 1073/4885
US-20030216409-A1 Heteroaryl alkyl piperazine derivatives ATP2A1, CPT1B, ATP2A3 ALDH1A1 110/4885TP53 3711/4885SMN1; SMN2 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.